Stifel analyst Annabel Samimy believe Express Scripts' accusations against specialty pharmacy Linden Care are "wholly unfounded" and believes that the impact of the halt is marginal for Horizon Pharma (HZNP), noting that only 5% of Horizon prescriptions flow through Linden and are processed by Express Scripts. The analyst, who noted that Express Scripts owns its own specialty pharmacy, Accredo, and said she views this public spat as "beginning to uncover the true nature of restrictive tactics of PBMs," keeps a Buy rating and $45 price target on Horizon shares.